Previous close | 1.8000 |
Open | 1.8000 |
Bid | 0.0000 |
Ask | 3.1000 |
Strike | 55.00 |
Expiry date | 2024-11-15 |
Day's range | 1.8000 - 1.8000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage b
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON, N.J., June 02, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 12 weeks in the Company’s Phase 2 clinical trial in c
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.